We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.4B
AUM Growth
+$210M
Cap. Flow
+$20.2M
Cap. Flow %
0.59%
Top 10 Hldgs %
33.65%
Holding
105
New
22
Increased
13
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$107M
2
CRBU icon
Caribou Biosciences
CRBU
+$100M
3
CYTK icon
Cytokinetics
CYTK
+$43.4M
4
SOPH icon
SOPHiA GENETICS
SOPH
+$35.6M
5
AZN icon
AstraZeneca
AZN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$166M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$68.5M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$43.5M
4
BIIB icon
Biogen
BIIB
+$37.8M
5
BAX icon
Baxter International
BAX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$53.2M 1.56%
300,545
+13,499
+5% +$2.17M
ICUI icon
27
ICU Medical
ICUI
$4.32B
$51.5M 1.51%
220,587
-35,121
-14% -$7.37M
HZNP
28
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$48.1M 1.42%
+439,400
New +$45.6M
PEN icon
29
Penumbra
PEN
$12.7B
$47.2M 1.39%
177,088
+43,329
+32% +$11.6M
AZN icon
30
AstraZeneca
AZN
$244B
$47.2M 1.39%
392,874
+288,574
+277% +$33.6M
GILD icon
31
Gilead Sciences
GILD
$161B
$46.6M 1.37%
666,601
– –
NVRO
32
DELISTED
NEVRO CORP.
NVRO
$45.7M 1.34%
392,786
-25,859
-6% -$3.38M
THC icon
33
Tenet Healthcare
THC
$20.2B
$44.3M 1.3%
667,073
– –
WAT icon
34
Waters Corp
WAT
$36.7B
$42M 1.24%
117,634
– –
ICLR icon
35
Icon
ICLR
$12.1B
$41.4M 1.22%
158,183
+13,956
+10% +$3.39M
NVAX icon
36
Novavax
NVAX
$1.22B
$40.9M 1.2%
197,208
+48,104
+32% +$10.6M
TMO icon
37
Thermo Fisher Scientific
TMO
$213B
$40.8M 1.2%
71,442
+36,613
+105% +$20.1M
BMY icon
38
CALL
Bristol-Myers Squibb
BMY
$132B
$36.2M 1.06%
+612,000
New +$40.3M
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$1.67B
$35.5M 1.04%
1,856,738
-288,143
-13% -$4.8M
SOPH icon
40
SOPHiA GENETICS
SOPH
$487M
$35.5M 1.04%
+2,022,552
New +$35.6M
HRTX icon
41
Heron Therapeutics
HRTX
$97.8M
$32M 0.94%
2,993,546
+794,489
+36% +$9.67M
JNCE
42
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$28.6M 0.84%
3,848,822
+585,989
+18% +$3.63M
CANO
43
DELISTED
Cano Health, Inc.
CANO
$26.6M 0.78%
20,943
– –
NBIX icon
44
CALL
Neurocrine Biosciences
NBIX
$16.9B
$25.1M 0.74%
+261,500
New +$24.7M
AERI
45
DELISTED
Aerie Pharmaceuticals
AERI
$24.9M 0.73%
2,182,684
– –
NTLA icon
46
Intellia Therapeutics
NTLA
$1.49B
$23.9M 0.7%
178,222
– –
CTLT
47
DELISTED
CATALENT, INC.
CTLT
$23.7M 0.7%
+177,800
New +$22.2M
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
$22.8M 0.67%
4,403,574
+775,674
+21% +$3.48M
KRTX
49
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$21.7M 0.64%
177,091
-16,295
-8% -$1.88M
ALLO icon
50
Allogene Therapeutics
ALLO
$625M
$19.9M 0.59%
775,819
+169,019
+28% +$4.01M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q3 2021 Portfolio in Review

As of Q3 2021, PFM Health Sciences held 105 positions worth $3.4B, up 6.6% from $3.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences's Q3 2021 filing shows 22 new, 13 increased, 16 reduced and 20 closed positions. Its largest new stake was Erasca: 5,191,405 shares worth $98.2M. The largest sale was Alexion Pharmaceuticals, an estimated $166M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier, followed by Financials.

  • PFM Health Sciences's largest Q3 2021 buy was Erasca: 5,191,405 shares worth $98.2M.
  • PFM Health Sciences added most to Cytokinetics in Q3 2021, an estimated $43.4M increase.
  • PFM Health Sciences's biggest Q3 2021 reduction was Biogen, cutting an estimated $37.8M.
  • PFM Health Sciences fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $166M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $3.4B portfolio in Q3 2021.
  • PFM Health Sciences opened 22 new positions and closed 20 in Q3 2021.
  • PFM Health Sciences's portfolio value rose 6.6% quarter-over-quarter to $3.4B.

Based on PFM Health Sciences's 13F filing for Q3 2021, filed 15 Nov 2021.